The effect of beta blocker use on bone outcomes using the Framingham Osteoporosis Study

Authors

Christine Lary, Maine Medical Center

Document Type

Video

Publication Date

5-1-2019

Institution/Department

Maine Medical Center Research Institute; Center for Outcomes Research and Evealuation

MeSH Headings

Adrenergic beta-Antagonists, Osteoporosis

Abstract

Background:

Bone fragility contributes to significant morbidity and mortality, increased medical costs, and decreased quality of life

-Over five billion dollars in annual hospital costs for older US women

-more costly that breast cancer, stroke, and myocardial infraction

Beta blockers (BBs) which competitively antagonize receptors in the sympathetic nervous system (SNS), improve bone metabolism and offer therapeutic benefit to patients at high risk of fracture.

Comments

Lambrew Research Retreat, Clinical & Population Health Research: Faculty Talk

Recommended Citation

Lary, Christine, "The effect of beta blocker use on bone outcomes using the Framingham Osteoporosis Study" (2019). MaineHealth Maine Medical Center. 715.
https://knowledgeconnection.mainehealth.org/mmc/715